Showing 1 - 1 results of 1 for search 'Accountancy', query time: 0.42s Refine Results
  1. 1
    Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
    by N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
    Published 2020-02-01
    “... medications and adverse event treatments were considered. We accounted for treatment discontinuation and CDK4...”
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search